BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 36794878)

  • 21. Intermittent Versus Continuous PEG-Asparaginase to Reduce Asparaginase-Associated Toxicities: A NOPHO ALL2008 Randomized Study.
    Albertsen BK; Grell K; Abrahamsson J; Lund B; Vettenranta K; Jónsson ÓG; Frandsen TL; Wolthers BO; Heyman M; Schmiegelow K
    J Clin Oncol; 2019 Jul; 37(19):1638-1646. PubMed ID: 30978155
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The use of prophylactic anticoagulation during induction and consolidation chemotherapy in adults with acute lymphoblastic leukemia.
    Grace RF; DeAngelo DJ; Stevenson KE; Neuberg D; Sallan SE; Mourad YRA; Bergeron J; Seftel MD; Kokulis C; Connors JM
    J Thromb Thrombolysis; 2018 Feb; 45(2):306-314. PubMed ID: 29260426
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prophylaxis of thromboembolism during therapy with asparaginase in adults with acute lymphoblastic leukaemia.
    Rank CU; Lynggaard LS; Als-Nielsen B; Stock W; Toft N; Nielsen OJ; Frandsen TL; Tuckuviene R; Schmiegelow K
    Cochrane Database Syst Rev; 2020 Oct; 10(10):CD013399. PubMed ID: 33038027
    [TBL] [Abstract][Full Text] [Related]  

  • 24. National Italian Delphi panel consensus: which measures are indicated to minimize pegylated-asparaginase associated toxicity during treatment of adult acute lymphoblastic leukemia?
    Lussana F; Minetto P; Ferrara F; Chiaretti S; Specchia G; Bassan R
    BMC Cancer; 2020 Oct; 20(1):956. PubMed ID: 33008391
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Advances on the role of pegaspargase in the treatment of childhood leukemia].
    Liu L; Xie XT
    Zhongguo Dang Dai Er Ke Za Zhi; 2014 Feb; 16(2):155-60. PubMed ID: 24568909
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Thromboembolism prophylaxis during L-asparaginase therapy in acute lymphoblastic leukemia - time to reconsider current approaches?
    Fulcher J; Carrier M
    Thromb Res; 2020 Apr; 188():100-102. PubMed ID: 32120278
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Toxicity profile of repeated doses of PEG-asparaginase incorporated into a pediatric-type regimen for adult acute lymphoblastic leukemia.
    Aldoss I; Douer D; Behrendt CE; Chaudhary P; Mohrbacher A; Vrona J; Pullarkat V
    Eur J Haematol; 2016 Apr; 96(4):375-80. PubMed ID: 26095294
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Incidence and risk factors for Central Nervous System thrombosis in paediatric acute lymphoblastic leukaemia during intensive asparaginase treatment: a single-centre cohort study.
    Duarte X; Esteves S; Neto AM; Pereira F
    Br J Haematol; 2016 Jul; 174(2):280-91. PubMed ID: 27018199
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Toxicity Profile of PEG-Asparaginase in Adult Patients With Acute Lymphoblastic Leukemia in Brazil: A Multicenter Cross-Sectional Study.
    Silva WFD; Massaut IHB; Bendlin RM; Rosa LI; Velloso EDRP; Rego EM; Rocha V
    Clin Lymphoma Myeloma Leuk; 2020 Aug; 20(8):e523-e528. PubMed ID: 32389674
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Anaphylactic reaction to polyethylene-glycol conjugated-asparaginase: premedication and desensitization may not be sufficient.
    Sahiner UM; Yavuz ST; Gökce M; Buyuktiryaki B; Altan I; Aytac S; Tuncer M; Tuncer A; Sackesen C
    Pediatr Int; 2013 Aug; 55(4):531-3. PubMed ID: 23910807
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Comparison of polyethylene glycol conjugated asparaginase and L-asparaginase for treatment of childhood acute lymphoblastic leukemia].
    Cooperation Group of Phase II Clinical Trial of PEG-Asp
    Zhonghua Xue Ye Xue Za Zhi; 2008 Jan; 29(1):29-33. PubMed ID: 18512312
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cerebral venous thrombosis in adult patients with acute lymphoblastic leukemia or lymphoblastic lymphoma during induction chemotherapy with l-asparaginase: The GRAALL experience.
    Couturier MA; Huguet F; Chevallier P; Suarez F; Thomas X; Escoffre-Barbe M; Cacheux V; Pignon JM; Bonmati C; Sanhes L; Bories P; Daguindau E; Dorvaux V; Reman O; Frayfer J; Orvain C; Lhéritier V; Ifrah N; Dombret H; Hunault-Berger M; Tanguy-Schmidt A
    Am J Hematol; 2015 Nov; 90(11):986-91. PubMed ID: 26214580
    [TBL] [Abstract][Full Text] [Related]  

  • 33. An open-label, multicenter study of polyethylene glycol-L-asparaginase for the treatment of acute lymphoblastic leukemia.
    Ettinger LJ; Kurtzberg J; Voûte PA; Jürgens H; Halpern SL
    Cancer; 1995 Mar; 75(5):1176-81. PubMed ID: 7850718
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of hypersensitivity rates to intravenous and intramuscular PEG-asparaginase in children with acute lymphoblastic leukemia: A meta-analysis and systematic review.
    Hasan H; Shaikh OM; Rassekh SR; Howard AF; Goddard K
    Pediatr Blood Cancer; 2017 Jan; 64(1):81-88. PubMed ID: 27578304
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparative Effectiveness of Peg-Asparaginase and L-Asparaginase on Coagulation Markers Among Pediatric Patients with Acute Lymphoblastic Leukemia.
    Zekavat OR; Safari A; Bordbar MR; Haghpanah S; Zareifar S; Shahriari M; Mohammadzadeh M
    Clin Lab; 2022 Feb; 68(2):. PubMed ID: 35142188
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Allergic Reactions Associated with Intravenous Versus Intramuscular Pegaspargase: A Retrospective Chart Review.
    Abbott LS; Zakova M; Shaikh F; Shewaramani N; Punnett A; Dupuis LL
    Paediatr Drugs; 2015 Aug; 17(4):315-21. PubMed ID: 25862348
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Incidence of venous thrombosis after peg-asparaginase in adolescent and young adults with acute lymphoblastic leukemia.
    Underwood B; Zhao Q; Walker AR; Mims AS; Vasu S; Long M; Z Haque T; Blaser BW; Grieselhuber NR; Wall SA; Behbehani GK; Blachly JS; Larkin K; Byrd JC; Garzon R; Wang TF; Bhatnagar B
    Int J Hematol Oncol; 2020 Sep; 9(3):IJH28. PubMed ID: 33014332
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pegylated-asparaginase during induction therapy for adult acute lymphoblastic leukaemia: toxicity data from the UKALL14 trial.
    Patel B; Kirkwood AA; Dey A; Marks DI; McMillan AK; Menne TF; Micklewright L; Patrick P; Purnell S; Rowntree CJ; Smith P; Fielding AK
    Leukemia; 2017 Jan; 31(1):58-64. PubMed ID: 27480385
    [TBL] [Abstract][Full Text] [Related]  

  • 39. L-asparaginase activity and anti-L-asparaginase antibody as biomarkers in estimating PEG-asp-related anaphylaxis risk in childhood acute lymphoblastic leukemia patients.
    Cui J; Jiang L; Xu B; Bai Y
    Allergol Immunopathol (Madr); 2023; 51(3):28-35. PubMed ID: 37169557
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Venous thromboembolism following pegaspargase in adults receiving antithrombin supplementation.
    Freyer CW; Carulli A; Ganetsky A; Hughes ME; Krause TM; Timlin C; Frey NV; Gill SI; Hexner EO; Loren AW; Mangan JK; Martin ME; McCurdy SR; Perl AE; Pratz K; Porter DL; Luger SM
    Leuk Lymphoma; 2020 Sep; 61(9):2200-2207. PubMed ID: 32482107
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.